Mir K. Lim

Internal Medicine
5323 Harry Hines Blvd 7201
Dallas, TX 75390

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Time to Double Down: Dual Immunotherapy as the Best Bet for Treatment of Microsatellite Instability-High Metastatic Colorectal Cancer.

Time to Double Down: Dual Immunotherapy as the Best Bet for Treatment of Microsatellite Instability-High Metastatic Colorectal Cancer.

Journal: Clinical colorectal cancer
Published: June 30, 2026

A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma.

A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma.

Journal: The oncologist
Published: September 29, 2025

Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma.

Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma.

Journal: JAMA network open
Published: February 25, 2025

A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study.

A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study.

Journal: Communications medicine
Published: March 08, 2024

Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.

Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.

Journal: Nature communications
Published: November 22, 2023

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.

Journal: Cancer research communications
Published: February 05, 2023

Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.

Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.

Journal: Gastroenterology
Published: February 01, 2023

Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.

Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)
Published: January 26, 2023

Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.

Journal: JCO precision oncology
Published: January 12, 2023

Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.

Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.

Journal: Cancer research communications
Published: January 10, 2023

EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma.

EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma.

Journal: Gastroenterology
Published: October 25, 2022

Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.

Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.

Journal: Nature communications
Published: July 05, 2022
Showing 1-12 of 16

Last Updated: 09/26/2026